ACADIA PHARMACEUTICALS INC — Director's Dealing 2017

Aug 11, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2017-08-09

Reporting Person: Baity Glenn (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-09	Common Stock	M	922	$1.55	Acquired	78578	Direct
2017-08-09	Common Stock	M	13400	$1.62	Acquired	91978	Direct
2017-08-09	Common Stock	S	14322	$34.8788	Disposed	77656	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-09	Stock Option (right to buy)	$1.55	M	922	Disposed	2020-03-11	Common Stock (922)	Direct
2017-08-09	Stock Option (right to buy)	$1.62	M	13400	Disposed	2021-03-24	Common Stock (13400)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $34.91 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

F3: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.